Table 3.

Namibia study participant characteristics and performance of PfHRP2 model with half-life of 4.5 days

ID	Characteristics						Model performance
	Age	Sex	Estimated weight (kg)	Enrolment parasitaemia (p/mL) × 106	Enrolment PfHRP2 (pg/mL) × 106	Follow up duration (days)	Number (%) observations in predicted interval	RSS	RMSE	Predicted days above 800 pg/mL	Last day observed above 800 pg/mL	Predicted days above 80 pg/mL	Last day observed above 80 pg/mL
F1	24	Male	61	9.46	0.83	84	2 (14%)	10.77	0.877	44.9	56	59.9	63
F2	25	Male	62	2.88	0.33	63	5 (50%)	1.56	0.395	34.3	35	49.3	42
F3	25	Female	58	0.10	0.002	21	1 (25%)	0.41	0.320	14.1	14	29.1	–
F4	24	Male	61	22.61	0.40	56	6 (67%)	1.43	0.399	47.7	42	62.7	–
F5	25	Female	58	0.39	3.66	28	3 (60%)	5.57	1.055	23.3	21	38.3	–
F6	24	Female	56.5	49.35	10,931.8	77	4 (31%)	19.3	1.217	54.9	56	69.9	70

Participant characteristics and model performance of the updated model with PfHRP2 half-life estimate of 4.5 days applied to 6 individuals aged between 23 and 27 years from the study in Namibia in participants with P. falciparum mono-infection

RSS residual sum of squares, RMSE root mean standard error calculated on the mid-point of the minimum and maximum predicted PfHRP2 concentrations—no observations were observed below 80 pg/mL so the last day above the threshold of 80 pg/mL was not able to be reported